Skip to main content
Journal cover image

Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia.

Publication ,  Journal Article
McCune, SL; Gockerman, JP; Moore, JO; Decastro, CM; Bass, AJ; Chao, NJ; Long, GD; Vredenburgh, JJ; Gasparetto, C; Adams, D; Payne, N; Rizzieri, DA
Published in: Leuk Lymphoma
May 2002

Twenty-three adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia (PLL) were treated for up to 12 weeks with the anti-CD52 monoclonal antibody alemtuzumab. Patients were a median of six years from diagnosis and had been treated with a median of four chemotherapy regimens (median of 24 total cycles) prior to enrollment. Fourteen patients (61%) had received prior monoclonal antibody therapy with rituximab. Adverse symptoms were primarily mild to moderate fever, rigor/chills, nausea/vomiting, or fatigue/malaise in up to 86% of patients. Patients with low blood counts at the initiation of alemtuzumab tolerated therapy well. A total of 17 patients were evaluable for disease response. Nine patients (53%) responded with complete remissions in the peripheral blood. Of these nine, five were evaluated by bone marrow biopsy with four complete responses (CR) and one partial response. Six of the nine presented with nodal disease at the start of alemtuzumab therapy with three CRs and three partial responses. Alemtuzumab is a monoclonal antibody that offers effective treatment for chemotherapy refractory CLL and PLL and is generally well tolerated in the outpatient setting.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Leuk Lymphoma

DOI

ISSN

1042-8194

Publication Date

May 2002

Volume

43

Issue

5

Start / End Page

1007 / 1011

Location

United States

Related Subject Headings

  • Middle Aged
  • Male
  • Leukemia, Prolymphocytic
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Immunology
  • Humans
  • Female
  • Antineoplastic Agents
  • Antibodies, Neoplasm
  • Antibodies, Monoclonal, Humanized
 

Citation

APA
Chicago
ICMJE
MLA
NLM
McCune, S. L., Gockerman, J. P., Moore, J. O., Decastro, C. M., Bass, A. J., Chao, N. J., … Rizzieri, D. A. (2002). Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Leuk Lymphoma, 43(5), 1007–1011. https://doi.org/10.1080/10428190290021597
McCune, Steven L., Jon P. Gockerman, Joseph O. Moore, Carlos M. Decastro, Adam J. Bass, Nelson J. Chao, Gwynn D. Long, et al. “Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia.Leuk Lymphoma 43, no. 5 (May 2002): 1007–11. https://doi.org/10.1080/10428190290021597.
McCune SL, Gockerman JP, Moore JO, Decastro CM, Bass AJ, Chao NJ, et al. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Leuk Lymphoma. 2002 May;43(5):1007–11.
McCune, Steven L., et al. “Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia.Leuk Lymphoma, vol. 43, no. 5, May 2002, pp. 1007–11. Pubmed, doi:10.1080/10428190290021597.
McCune SL, Gockerman JP, Moore JO, Decastro CM, Bass AJ, Chao NJ, Long GD, Vredenburgh JJ, Gasparetto C, Adams D, Payne N, Rizzieri DA. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Leuk Lymphoma. 2002 May;43(5):1007–1011.
Journal cover image

Published In

Leuk Lymphoma

DOI

ISSN

1042-8194

Publication Date

May 2002

Volume

43

Issue

5

Start / End Page

1007 / 1011

Location

United States

Related Subject Headings

  • Middle Aged
  • Male
  • Leukemia, Prolymphocytic
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Immunology
  • Humans
  • Female
  • Antineoplastic Agents
  • Antibodies, Neoplasm
  • Antibodies, Monoclonal, Humanized